Juvenile Arthritis News

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

WASHINGTON — Patients with juvenile idiopathic arthritis receive biologic disease-modifying antirheumatic drugs significantly sooner on public insurance vs. private, particularly if they have oligoarticular JIA, according to a speaker.

Only 49.1% of available pediatric rheumatology fellowship slots were filled for 2025 on this year’s Match Day, representing a sharper drop-off for the specialty after years of trickling declines.

The FDA has granted rare pediatric disease designation to a type IA prodrug of dexamethasone that targets CD206+ macrophages for the treatment of systemic juvenile idiopathic arthritis flares, according to a press release from PIF Partners.

WASHINGTON — Children with lupus from areas of lower socioeconomic opportunity experience more severe disease complications and poorer outcomes than those from higher opportunity areas, according to data presented at ACR Convergence 2024.

WASHINGTON — A focus on patient follow-up, standardized medication adherence and barriers assessments can reduce racial and ethnic disparities in juvenile idiopathic arthritis, according to a speaker at ACR Convergence 2024.

The FDA has expanded the approval of an oral liquid methotrexate solution to include children and adolescents with polyarticular juvenile idiopathic arthritis and acute lymphoblastic leukemia, according to a press release.

In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more.

Intravenous golimumab yielded a durable clinical response through 116 weeks, with a stable safety profile, in polyarticular-course juvenile idiopathic arthritis, according to data published in The Journal of Rheumatology.